Your browser doesn't support javascript.
loading
Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM).
Nakayama, Takahiro; Niikura, Naoki; Yamanaka, Takashi; Yamamoto, Mitsugu; Matsuura, Kazuo; Inoue, Kenichi; Takahara, Sachiko; Nomura, Hironori; Kita, Shosuke; Yamaguchi, Miki; Aruga, Tomoyuki; Shibata, Nobuhiro; Shimomura, Akihiko; Ozaki, Yuri; Sakai, Shuji; Takiguchi, Daisuke; Takata, Takehiko; Bastanfard, Armin; Shiosakai, Kazuhito; Tsurutani, Junji.
Afiliación
  • Nakayama T; Department of Breast and Endocrine Surgery, Osaka International Cancer Institute, Osaka, Japan.
  • Niikura N; Department of Breast Oncology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan. nniikura@tokai.ac.jp.
  • Yamanaka T; Department of Breast Surgery and Oncology, Kanagawa Cancer Center, Kanagawa, Japan.
  • Yamamoto M; Department of Breast Oncology, Hokkaido Cancer Center, Hokkaido, Japan.
  • Matsuura K; Department of Breast Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
  • Inoue K; Division of Breast Oncology, Saitama Cancer Center, Saitama, Japan.
  • Takahara S; Department of Breast Surgery, Kitano Hospital, Osaka, Japan.
  • Nomura H; First Department of Surgery, University of the Ryukyus Hospital, Okinawa, Japan.
  • Kita S; Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Yamaguchi M; Department of Breast Surgery, JCHO Kurume General Hospital, Fukuoka, Japan.
  • Aruga T; Department of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
  • Shibata N; Cancer Treatment Center, Kansai Medical University Hospital, Osaka, Japan.
  • Shimomura A; Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan.
  • Ozaki Y; Department of Breast Oncology, Aichi Cancer Center, Aichi, Japan.
  • Sakai S; Department of Diagnostic Imaging and Nuclear Medicine, Tokyo Women's Medical University, Tokyo, Japan.
  • Takiguchi D; Oncology Medical Science Department I, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
  • Takata T; Oncology Medical Science Department I, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
  • Bastanfard A; Oncology Medical Science Department I, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
  • Shiosakai K; Data Intelligence Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
  • Tsurutani J; Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan.
Breast Cancer ; 2024 Aug 12.
Article en En | MEDLINE | ID: mdl-39133378
ABSTRACT
We provide updated results (median follow-up duration 20.4 months) of a retrospective study on the effectiveness of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer with brain metastases (BM) and/or leptomeningeal disease (ROSET-BM). Median progression-free survival (PFS) was 14.6 months. Median overall survival (OS) was not reached (NR); 24-month OS rate was 56.0%. Subgroup analysis showed that median PFS was 13.2 months in patients with analytical active BM, 17.5 months in patients with leptomeningeal carcinomatosis (LMC), and NR in patients with analytical stable BM (24-month PFS rates in patients with analytical active BM, LMC, and analytical stable BM were 32.7%, 25.1%, and 60.8%, respectively). Median OS was 27.0 months in patients with analytical active BM and NR in patients with LMC or analytical stable BM (24-month OS rates in patients with analytical active BM, LMC, and analytical stable BM were 52.0%, 61.6%, and 71.6%, respectively). The most common adverse event leading to discontinuation of T-DXd was interstitial lung disease (ILD; 23.1%); median ILD onset time among patients who discontinued T-DXd treatment due to ILD was 5.3 months. T-DXd has promising effectiveness in heavily pre-treated HER2+ metastatic breast cancer patients with BM and LMC. The incidence and median onset time of ILD were similar to those of Japanese subgroups in previous studies.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Breast Cancer Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Japón
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Breast Cancer Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Japón